NOVARTIS INDIA LTD. - 500672 - Board recommends Final Dividend (AGM on August 07, 2020)
Novartis India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 19, 2020, inter alia, have approved :- Recommendation of final dividend of Rs. 10/- per Equity share of Rs. 5/- each for the year ended March 31, 2020, subject to approval of the shareholders of the Company. NOVARTIS INDIA LTD. - 500672 - Outcome Of The Meeting Of The Board Of Directors Of Novartis India Limited ('The Company') Held On June 19, 2020
Kindly note that the Board of Directors of the Company has in its meeting held today, inter alia have approved: 1.Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2020;2.Recommendation of final dividend of Rs. 10/- per Equity share of Rs. 5/- each for the year ended March 31, 2020, subject to approval of the shareholders of the Company;3.Appointment of Mr. Sanker Parameswaran as an Additional Director (Independent and Non-Executive) of the Company, to hold office for a period of 5 consecutive years with effect from June 22, 2020. His appointment as an Independent Director will be subject to approval of the shareholders of the Company; The said Meeting commenced at 11:45 a.m. and concluded at 2:05 p.m. Detailed outcome of the BM and matters approved is enclosed herewith. NOVARTIS INDIA LTD. - 500672 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Dear Sirs, Apropos the subject matter quoted above, please find enclosed herewith the copies of the newspaper Notices in 'Financial Express' and 'Navshakti' on June 12, 2020. This is for your information and record. Thanking You. NOVARTIS INDIA LTD. - 500672 - Board Meeting Intimation for Considering The Audited Financial Results Of The Company For The Fourth Quarter And Financial Year Ended March 31, 2020 And Recommendation Of Final Dividend On Equity Share, If Any, For The Said Year.
NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/06/2020 ,inter alia, to consider and approve the Audited Financial Results of the Company for the fourth quarter and Financial Year ended March 31, 2020 and recommendation of final dividend on Equity Share, if any, for the said year. Further, please note that pursuant to the Company''s Code of Conduct for regulating, monitoring and reporting share trading by designated persons, as informed earlier vide our letter dated March 31, 2020, the trading window for dealing in securities of the Company is closed from Wednesday, April 1, 2020 and shall continue to be closed till June 21, 2020 (both days inclusive). The trading window shall re-open with effect from June 22, 2020. Further, a copy of this notice will be published in the selected newspapers and will be made available on the website of the Company www.novartis.in. NOVARTIS INDIA LTD. - 500672 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayNOVARTIS INDIA LTD. 2CINL24200MH1947PLC006104 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Trivikram Guda Designation: Company Secretary and Compliance Officer EmailId: trivikram.guda@novartis.com Name of the Chief Financial Officer: Felix Doss Designation: Chief Financial Officer EmailId: felix.doss@novartis.com Date: 01/06/2020 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Vaccine for coronavirus won't be ready for at least 2 years: Novartis CEO
A vaccine must be widely tested in humans before being administered to hundreds of millions, say experts. NOVARTIS INDIA LTD. - 500672 - Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- Trivikram GudaDesignation :- Company Secretary and Compliance Officer NOVARTIS INDIA LTD. - 500672 - Compliance Certificate Obtained By Novartis India Limited ('The Company') From A Practising Company Secretary For The Half Year Ended On March 31, 2020, In Terms Of The Provisions Of Regulations 40(9) & (10) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")
Please note that in terms of the SEBI Listing Regulations, the Company has obtained a Compliance Certificate from Saraf & Associates, Company Secretaries, for the half year ended on March 31, 2020 and the same is being submitted herewith. This is for your information and record. NOVARTIS INDIA LTD. - 500672 - Compliance Certificate Obtained By Novartis India Limited ('The Company') From A Practising Company Secretary For The Half Year Ended On March 31, 2020, In Terms Of The Provisions Of Regulations 40(9) & (10) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")
Please note that in terms of the SEBI Listing Regulations, the Company has obtained a Compliance Certificate from Saraf & Associates, Company Secretaries, for the half year ended on March 31, 2020 and the same is being submitted herewith. This is for your information and record.